Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
29 April 1986Website:
http://www.repligen.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 17:30:59 GMTDividend
Analysts recommendations
Institutional Ownership
RGEN Latest News
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.
Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024 Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024
Repligen (RGEN) reported lower-than-expected earnings in the first quarter of 2024, but surpassed revenue estimates.
Repligen (RGEN) reported earnings of $0.28 per share for the quarter, falling short of the Zacks Consensus Estimate of $0.29 per share. This is lower than the earnings of $0.64 per share in the same quarter last year.
Webcast and Conference Call scheduled for Wednesday, May 1, 2024, at 8:30 a.m. ET.
Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.
Repligen (RGEN) came out with quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.68 per share a year ago.
Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 1(current)
What type of business is Repligen?
Repligen Corporation is a global biotechnology company that develops and commercializes highly innovative biotechnological technologies and systems to enhance the efficiency and flexibility of the production process of biological products. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. The company's business is represented by a product line: Chromatography; Filtration; Process Analytics; Protein products; Other. Customers use the company's products for the production of drugs for clinical trials, then scale up to larger volumes as the drug transitions to commercial production after regulatory approval. Repligen Corporation's customers include biopharmaceutical companies, contract development organizations, and manufacturing organizations.
What sector is Repligen in?
Repligen is in the Healthcare sector
What industry is Repligen in?
Repligen is in the Medical Instruments & Supplies industry
What country is Repligen from?
Repligen is headquartered in United States
When did Repligen go public?
Repligen initial public offering (IPO) was on 29 April 1986
What is Repligen website?
https://www.repligen.com
Is Repligen in the S&P 500?
No, Repligen is not included in the S&P 500 index
Is Repligen in the NASDAQ 100?
No, Repligen is not included in the NASDAQ 100 index
Is Repligen in the Dow Jones?
No, Repligen is not included in the Dow Jones index
When does Repligen report earnings?
The next expected earnings date for Repligen is 02 August 2024